François Anna
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
François Anna has a total of 175 co-authors. Here are the top co-authors by number of shared publications:
- Charles-Frédéric Mantion
Université Marie et Louis Pasteur, EFS, INSERM UMR1098 RIGHT, Besançon, France
13 shared publications - Elodie Bôle-Richard
FC Innov’, Bionovéo, Besançon, France. 4
13 shared publications - Eric Deconinck
Hôpital Jean Minjoz, Besançon, France
13 shared publications - Eric Robinet
Lymphobank S.A.S.U, Besançon, France. 9
13 shared publications - Etienne Daguidau
Service d'Hématologie, Hopital Jean Minjoz Besancon France
13 shared publications - Evan Seffar
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
13 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S2: Characterization of CD123 CAR-T.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S2: Characterization of CD123 CAR-T.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S1: Design of five CD123 CAR-T constructs.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S1: Design of five CD123 CAR-T constructs.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S4 Effect of CD123 CAR-T on humanized mouse model, NSG-SGM3.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S4 Effect of CD123 CAR-T on humanized mouse model, NSG-SGM3.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S3: Effect of CD123 CAR-T on human Hematopoietic stem cell.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S3: Effect of CD123 CAR-T on human Hematopoietic stem cell.
- Open Access
- 4 July 2025
- Published by Springer Nature in npj Vaccines
- Vol. 10 (1) , 1-14
Optimized lentiviral backbone induces robust and diverse T cell immunity against neoantigens to counteract tumor heterogeneity
Targeting personalized tumor neoantigens is a promising strategy in immuno-oncotherapy, tumor heterogeneity requires that adaptive immunity be effectively induced against a broad spectrum of neoantigens for a significant anti-tumor effect. We developed several non-integrative lentiviral vectors encoding optimized immunogen that induce robust T cell responses against neoepitopes derived from murine colorectal tumors. Incorporating proteasome-targeting sequences and 4-alanine spacers between neoepitopes enhanced responses to both dominant and subdominant neoepitopes. Using longer natural sequences encompassing minimal epitopes further improved immunogenicity. These vectors drove complete regression of MC38 tumors expressing the selected neoepitopes and sustained immune memory to prevent relapse. Additionally, these vectors synergized with anti-programmed cell death protein 1 (PD1) therapy to inhibit wild-type MC38 tumor growth. Variant allele frequency tracking demonstrated T cells eradicated neoantigen-positive cells without affecting negative ones. Our results validate lentiviral vectors for personalized neoepitope therapy and underscore the need for diverse neoantigens in immunotherapy against tumor mosaicism.
- 4 July 2025
- Published by Springer Nature in npj Vaccines
- Vol. 10 (1) , 1-14
Open AccessOptimized lentiviral backbone induces robust and diverse T cell immunity against neoantigens to counteract tumor heterogeneity
Targeting personalized tumor neoantigens is a promising strategy in immuno-oncotherapy, tumor heterogeneity requires that adaptive immunity be effectively induced against a broad spectrum of neoantigens for a significant anti-tumor effect. We developed several non-integrative lentiviral vectors encoding optimized immunogen that induce robust T cell responses against neoepitopes derived from murine colorectal tumors. Incorporating proteasome-targeting sequences and 4-alanine spacers between neoepitopes enhanced responses to both dominant and subdominant neoepitopes. Using longer natural sequences encompassing minimal epitopes further improved immunogenicity. These vectors drove complete regression of MC38 tumors expressing the selected neoepitopes and sustained immune memory to prevent relapse. Additionally, these vectors synergized with anti-programmed cell death protein 1 (PD1) therapy to inhibit wild-type MC38 tumor growth. Variant allele frequency tracking demonstrated T cells eradicated neoantigen-positive cells without affecting negative ones. Our results validate lentiviral vectors for personalized neoepitope therapy and underscore the need for diverse neoantigens in immunotherapy against tumor mosaicism.
- Open Access
Optimized pipeline for generating highly potent neutralizing Affitins: application to SARS-CoV-2 spike protein
Viral infections represent a global health threat, causing three million deaths annually. Antiviral strategies primarily target viral genome replication or prevent virus entry into host cells. While most FDA-approved antiviral drugs are small chemical molecules, protein-based therapies like monoclonal antibodies (mAbs) offer advantages such as broad and high neutralizing activities, and ability to recruit immune responses to enhance viral clearance. Additionally, alternative protein scaffolds with favorable properties have been developed to substitute or complement mAbs. We have developed Affitins, a novel class of small artificial affinity proteins (7 kDa) derived from hyperthermophilic archaea. Affitins, selected from high-diversity libraries (∼10 12 variants) against any target protein, are highly stable, easy to engineer, and cost-effective to produce. Here, we developed a pipeline to generate Affitins in different multimerization formats targeting the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein through ribosome display selection and assessed their efficacy. The most potent candidates, dimerized or trimerized into 17–27 kDa proteins, displayed high thermal stability, strong binding affinities, and potent neutralization against various SARS-CoV-2 variants, with IC 50 values as low as 32 pM. We also report the first hexameric Affitins, formed by dimerizing trimers through Fc fragment fusion (∼106 kDa), achieving potent neutralization with an IC 50 of 0.8 pM, ranking them among the most potent B1.351 SARS-Cov-2 neutralizing proteins. Our findings highlight Affitins as promising antiviral agents, demonstrating their versatility for engineering affinity proteins with higher valencies than that of antibodies while retaining a lower molecular weight, thereby expanding the toolkit for combating viral threats.
Open AccessOptimized pipeline for generating highly potent neutralizing Affitins: application to SARS-CoV-2 spike protein
Viral infections represent a global health threat, causing three million deaths annually. Antiviral strategies primarily target viral genome replication or prevent virus entry into host cells. While most FDA-approved antiviral drugs are small chemical molecules, protein-based therapies like monoclonal antibodies (mAbs) offer advantages such as broad and high neutralizing activities, and ability to recruit immune responses to enhance viral clearance. Additionally, alternative protein scaffolds with favorable properties have been developed to substitute or complement mAbs. We have developed Affitins, a novel class of small artificial affinity proteins (7 kDa) derived from hyperthermophilic archaea. Affitins, selected from high-diversity libraries (∼10 12 variants) against any target protein, are highly stable, easy to engineer, and cost-effective to produce. Here, we developed a pipeline to generate Affitins in different multimerization formats targeting the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein through ribosome display selection and assessed their efficacy. The most potent candidates, dimerized or trimerized into 17–27 kDa proteins, displayed high thermal stability, strong binding affinities, and potent neutralization against various SARS-CoV-2 variants, with IC 50 values as low as 32 pM. We also report the first hexameric Affitins, formed by dimerizing trimers through Fc fragment fusion (∼106 kDa), achieving potent neutralization with an IC 50 of 0.8 pM, ranking them among the most potent B1.351 SARS-Cov-2 neutralizing proteins. Our findings highlight Affitins as promising antiviral agents, demonstrating their versatility for engineering affinity proteins with higher valencies than that of antibodies while retaining a lower molecular weight, thereby expanding the toolkit for combating viral threats.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Figure S4 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S4 Effect of CD123 CAR-T on humanized mouse model, NSG-SGM3.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S4 Effect of CD123 CAR-T on humanized mouse model, NSG-SGM3.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S2: Characterization of CD123 CAR-T.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S2: Characterization of CD123 CAR-T.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Figure S3 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S3: Effect of CD123 CAR-T on human Hematopoietic stem cell.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S3: Effect of CD123 CAR-T on human Hematopoietic stem cell.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Figure S1 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S1: Design of five CD123 CAR-T constructs.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells
Supplementary Figure S1: Design of five CD123 CAR-T constructs.